Evaluation of the effects of L-carnitine on medaka (Oryzias latipes) fatty liver

Lifestyle-related diseases have become a major issue in recent years. The increasing incidence of fatty liver underlines the urgency with which the issues of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) need to be addressed. L-carnitine is a compound known to tr...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2017-06, Vol.7 (1), p.2749-10, Article 2749
Main Authors: Fujisawa, Koichi, Takami, Taro, Matsuzaki, Aya, Matsumoto, Toshihiko, Yamamoto, Naoki, Terai, Shuji, Sakaida, Isao
Format: Article
Language:English
Subjects:
101/58
631/443/319/2723
631/443/319/320
82/1
Alcohol use
Animals
Biomarkers
Body Weight
Carnitine
Carnitine - pharmacology
Diet, High-Fat
Disease Models, Animal
Eicosapentaenoic acid
Fatty acid composition
Fatty acids
Fatty Acids - metabolism
Fatty liver
Fatty Liver - drug therapy
Fatty Liver - etiology
Fatty Liver - metabolism
Fatty Liver - pathology
Humanities and Social Sciences
Lipid Metabolism - drug effects
Liver
Liver - drug effects
Liver - metabolism
Liver - pathology
Liver diseases
Liver Function Tests
Metabolites
Metabolome
Metabolomics - methods
Mitochondria
Mitochondria - drug effects
Mitochondria - metabolism
multidisciplinary
Oryzias - metabolism
Oryzias latipes
Oxidation
Oxidation-Reduction - drug effects
Science
Science (multidisciplinary)
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c606t-dfa4e171f62b597ac7f084cfa44ee007a5364c1f7a8004cfc493eef546b7b8543
cites cdi_FETCH-LOGICAL-c606t-dfa4e171f62b597ac7f084cfa44ee007a5364c1f7a8004cfc493eef546b7b8543
container_end_page 10
container_issue 1
container_start_page 2749
container_title Scientific reports
container_volume 7
creator Fujisawa, Koichi
Takami, Taro
Matsuzaki, Aya
Matsumoto, Toshihiko
Yamamoto, Naoki
Terai, Shuji
Sakaida, Isao
description Lifestyle-related diseases have become a major issue in recent years. The increasing incidence of fatty liver underlines the urgency with which the issues of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) need to be addressed. L-carnitine is a compound known to transport fatty acids into the mitochondria to enhance β-oxidation-mediated metabolism of fats. In this study, the effects of L-carnitine administration on fatty liver of medaka ( Oryzias latipes ) were analysed, to check for disease improvement and metabolic changes. Additionally, the effects of the concomitant administration of L-carnitine and eicosapentaenoic acid (20:5n-3) (EPA) were investigated. Findings indicated reduced lipid deposition, increase in metabolites associated with β-oxidation, and significant reduction in fatty acid levels in the liver, implying improvement in fatty liver condition. Concomitant administration of L-carnitine and EPA resulted in further benefits, via changes in fatty acid composition in the medaka fatty liver model.
doi_str_mv 10.1038/s41598-017-02924-5
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_56d754f1cc8f4367970dc3b3c98f3e0e</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_56d754f1cc8f4367970dc3b3c98f3e0e</doaj_id><sourcerecordid>1906465744</sourcerecordid><originalsourceid>FETCH-LOGICAL-c606t-dfa4e171f62b597ac7f084cfa44ee007a5364c1f7a8004cfc493eef546b7b8543</originalsourceid><addsrcrecordid>eNp1kU1v1DAQhi0EolXpH-CAInEph4C_7VyQUFWgUqVygLPlOOOtl2y82M5Ky6_H25Rqi4Qv9ozfeTzjF6HXBL8nmOkPmRPR6RYT1WLaUd6KZ-iUYi5ayih9fnQ-Qec5r3FdgnacdC_RCdVC8xqcom9XOzvOtoQ4NdE35Q4a8B5cyYfwpnU2TaGECZoq2MBgf9rm4jbtfwebm7HWbSG_a7wtZd-MYQfpFXrh7Zjh_GE_Qz8-X32__Nre3H65vvxUiRLL0g7eciCKeEl70SnrlMeau5rlABgrK5jkjnhlNcY173jHALzgsle9FpydoeuFO0S7NtsUNjbtTbTB3CdiWhmbSnAjGCEHJbgnzmnPmVSdwoNjPXOd9gwwVNbHhbWd-zqjg6kkOz6BPr2Zwp1ZxZ0RvHogaQVcPABS_DVDLmYTsoNxtBPEORvSYcmlUPzQ99t_pOs4p6l-VVUJITjXilQVXVQuxZwT-MdmCDYH_83iv6n-m3v_jahFb47HeCz563YVsEWQ69W0gnT09v-xfwDdUbrG</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1955544871</pqid></control><display><type>article</type><title>Evaluation of the effects of L-carnitine on medaka (Oryzias latipes) fatty liver</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>Free Full-Text Journals in Chemistry</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Fujisawa, Koichi ; Takami, Taro ; Matsuzaki, Aya ; Matsumoto, Toshihiko ; Yamamoto, Naoki ; Terai, Shuji ; Sakaida, Isao</creator><creatorcontrib>Fujisawa, Koichi ; Takami, Taro ; Matsuzaki, Aya ; Matsumoto, Toshihiko ; Yamamoto, Naoki ; Terai, Shuji ; Sakaida, Isao</creatorcontrib><description>Lifestyle-related diseases have become a major issue in recent years. The increasing incidence of fatty liver underlines the urgency with which the issues of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) need to be addressed. L-carnitine is a compound known to transport fatty acids into the mitochondria to enhance β-oxidation-mediated metabolism of fats. In this study, the effects of L-carnitine administration on fatty liver of medaka ( Oryzias latipes ) were analysed, to check for disease improvement and metabolic changes. Additionally, the effects of the concomitant administration of L-carnitine and eicosapentaenoic acid (20:5n-3) (EPA) were investigated. Findings indicated reduced lipid deposition, increase in metabolites associated with β-oxidation, and significant reduction in fatty acid levels in the liver, implying improvement in fatty liver condition. Concomitant administration of L-carnitine and EPA resulted in further benefits, via changes in fatty acid composition in the medaka fatty liver model.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-017-02924-5</identifier><identifier>PMID: 28584294</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>101/58 ; 631/443/319/2723 ; 631/443/319/320 ; 82/1 ; Alcohol use ; Animals ; Biomarkers ; Body Weight ; Carnitine ; Carnitine - pharmacology ; Diet, High-Fat ; Disease Models, Animal ; Eicosapentaenoic acid ; Fatty acid composition ; Fatty acids ; Fatty Acids - metabolism ; Fatty liver ; Fatty Liver - drug therapy ; Fatty Liver - etiology ; Fatty Liver - metabolism ; Fatty Liver - pathology ; Humanities and Social Sciences ; Lipid Metabolism - drug effects ; Liver ; Liver - drug effects ; Liver - metabolism ; Liver - pathology ; Liver diseases ; Liver Function Tests ; Metabolites ; Metabolome ; Metabolomics - methods ; Mitochondria ; Mitochondria - drug effects ; Mitochondria - metabolism ; multidisciplinary ; Oryzias - metabolism ; Oryzias latipes ; Oxidation ; Oxidation-Reduction - drug effects ; Science ; Science (multidisciplinary) ; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</subject><ispartof>Scientific reports, 2017-06, Vol.7 (1), p.2749-10, Article 2749</ispartof><rights>The Author(s) 2017</rights><rights>Copyright Nature Publishing Group Jun 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c606t-dfa4e171f62b597ac7f084cfa44ee007a5364c1f7a8004cfc493eef546b7b8543</citedby><cites>FETCH-LOGICAL-c606t-dfa4e171f62b597ac7f084cfa44ee007a5364c1f7a8004cfc493eef546b7b8543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1955544871/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1955544871?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28584294$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fujisawa, Koichi</creatorcontrib><creatorcontrib>Takami, Taro</creatorcontrib><creatorcontrib>Matsuzaki, Aya</creatorcontrib><creatorcontrib>Matsumoto, Toshihiko</creatorcontrib><creatorcontrib>Yamamoto, Naoki</creatorcontrib><creatorcontrib>Terai, Shuji</creatorcontrib><creatorcontrib>Sakaida, Isao</creatorcontrib><title>Evaluation of the effects of L-carnitine on medaka (Oryzias latipes) fatty liver</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Lifestyle-related diseases have become a major issue in recent years. The increasing incidence of fatty liver underlines the urgency with which the issues of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) need to be addressed. L-carnitine is a compound known to transport fatty acids into the mitochondria to enhance β-oxidation-mediated metabolism of fats. In this study, the effects of L-carnitine administration on fatty liver of medaka ( Oryzias latipes ) were analysed, to check for disease improvement and metabolic changes. Additionally, the effects of the concomitant administration of L-carnitine and eicosapentaenoic acid (20:5n-3) (EPA) were investigated. Findings indicated reduced lipid deposition, increase in metabolites associated with β-oxidation, and significant reduction in fatty acid levels in the liver, implying improvement in fatty liver condition. Concomitant administration of L-carnitine and EPA resulted in further benefits, via changes in fatty acid composition in the medaka fatty liver model.</description><subject>101/58</subject><subject>631/443/319/2723</subject><subject>631/443/319/320</subject><subject>82/1</subject><subject>Alcohol use</subject><subject>Animals</subject><subject>Biomarkers</subject><subject>Body Weight</subject><subject>Carnitine</subject><subject>Carnitine - pharmacology</subject><subject>Diet, High-Fat</subject><subject>Disease Models, Animal</subject><subject>Eicosapentaenoic acid</subject><subject>Fatty acid composition</subject><subject>Fatty acids</subject><subject>Fatty Acids - metabolism</subject><subject>Fatty liver</subject><subject>Fatty Liver - drug therapy</subject><subject>Fatty Liver - etiology</subject><subject>Fatty Liver - metabolism</subject><subject>Fatty Liver - pathology</subject><subject>Humanities and Social Sciences</subject><subject>Lipid Metabolism - drug effects</subject><subject>Liver</subject><subject>Liver - drug effects</subject><subject>Liver - metabolism</subject><subject>Liver - pathology</subject><subject>Liver diseases</subject><subject>Liver Function Tests</subject><subject>Metabolites</subject><subject>Metabolome</subject><subject>Metabolomics - methods</subject><subject>Mitochondria</subject><subject>Mitochondria - drug effects</subject><subject>Mitochondria - metabolism</subject><subject>multidisciplinary</subject><subject>Oryzias - metabolism</subject><subject>Oryzias latipes</subject><subject>Oxidation</subject><subject>Oxidation-Reduction - drug effects</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1kU1v1DAQhi0EolXpH-CAInEph4C_7VyQUFWgUqVygLPlOOOtl2y82M5Ky6_H25Rqi4Qv9ozfeTzjF6HXBL8nmOkPmRPR6RYT1WLaUd6KZ-iUYi5ayih9fnQ-Qec5r3FdgnacdC_RCdVC8xqcom9XOzvOtoQ4NdE35Q4a8B5cyYfwpnU2TaGECZoq2MBgf9rm4jbtfwebm7HWbSG_a7wtZd-MYQfpFXrh7Zjh_GE_Qz8-X32__Nre3H65vvxUiRLL0g7eciCKeEl70SnrlMeau5rlABgrK5jkjnhlNcY173jHALzgsle9FpydoeuFO0S7NtsUNjbtTbTB3CdiWhmbSnAjGCEHJbgnzmnPmVSdwoNjPXOd9gwwVNbHhbWd-zqjg6kkOz6BPr2Zwp1ZxZ0RvHogaQVcPABS_DVDLmYTsoNxtBPEORvSYcmlUPzQ99t_pOs4p6l-VVUJITjXilQVXVQuxZwT-MdmCDYH_83iv6n-m3v_jahFb47HeCz563YVsEWQ69W0gnT09v-xfwDdUbrG</recordid><startdate>20170605</startdate><enddate>20170605</enddate><creator>Fujisawa, Koichi</creator><creator>Takami, Taro</creator><creator>Matsuzaki, Aya</creator><creator>Matsumoto, Toshihiko</creator><creator>Yamamoto, Naoki</creator><creator>Terai, Shuji</creator><creator>Sakaida, Isao</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><general>Nature Portfolio</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20170605</creationdate><title>Evaluation of the effects of L-carnitine on medaka (Oryzias latipes) fatty liver</title><author>Fujisawa, Koichi ; Takami, Taro ; Matsuzaki, Aya ; Matsumoto, Toshihiko ; Yamamoto, Naoki ; Terai, Shuji ; Sakaida, Isao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c606t-dfa4e171f62b597ac7f084cfa44ee007a5364c1f7a8004cfc493eef546b7b8543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>101/58</topic><topic>631/443/319/2723</topic><topic>631/443/319/320</topic><topic>82/1</topic><topic>Alcohol use</topic><topic>Animals</topic><topic>Biomarkers</topic><topic>Body Weight</topic><topic>Carnitine</topic><topic>Carnitine - pharmacology</topic><topic>Diet, High-Fat</topic><topic>Disease Models, Animal</topic><topic>Eicosapentaenoic acid</topic><topic>Fatty acid composition</topic><topic>Fatty acids</topic><topic>Fatty Acids - metabolism</topic><topic>Fatty liver</topic><topic>Fatty Liver - drug therapy</topic><topic>Fatty Liver - etiology</topic><topic>Fatty Liver - metabolism</topic><topic>Fatty Liver - pathology</topic><topic>Humanities and Social Sciences</topic><topic>Lipid Metabolism - drug effects</topic><topic>Liver</topic><topic>Liver - drug effects</topic><topic>Liver - metabolism</topic><topic>Liver - pathology</topic><topic>Liver diseases</topic><topic>Liver Function Tests</topic><topic>Metabolites</topic><topic>Metabolome</topic><topic>Metabolomics - methods</topic><topic>Mitochondria</topic><topic>Mitochondria - drug effects</topic><topic>Mitochondria - metabolism</topic><topic>multidisciplinary</topic><topic>Oryzias - metabolism</topic><topic>Oryzias latipes</topic><topic>Oxidation</topic><topic>Oxidation-Reduction - drug effects</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fujisawa, Koichi</creatorcontrib><creatorcontrib>Takami, Taro</creatorcontrib><creatorcontrib>Matsuzaki, Aya</creatorcontrib><creatorcontrib>Matsumoto, Toshihiko</creatorcontrib><creatorcontrib>Yamamoto, Naoki</creatorcontrib><creatorcontrib>Terai, Shuji</creatorcontrib><creatorcontrib>Sakaida, Isao</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Science Journals</collection><collection>ProQuest Biological Science Journals</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fujisawa, Koichi</au><au>Takami, Taro</au><au>Matsuzaki, Aya</au><au>Matsumoto, Toshihiko</au><au>Yamamoto, Naoki</au><au>Terai, Shuji</au><au>Sakaida, Isao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of the effects of L-carnitine on medaka (Oryzias latipes) fatty liver</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2017-06-05</date><risdate>2017</risdate><volume>7</volume><issue>1</issue><spage>2749</spage><epage>10</epage><pages>2749-10</pages><artnum>2749</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Lifestyle-related diseases have become a major issue in recent years. The increasing incidence of fatty liver underlines the urgency with which the issues of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) need to be addressed. L-carnitine is a compound known to transport fatty acids into the mitochondria to enhance β-oxidation-mediated metabolism of fats. In this study, the effects of L-carnitine administration on fatty liver of medaka ( Oryzias latipes ) were analysed, to check for disease improvement and metabolic changes. Additionally, the effects of the concomitant administration of L-carnitine and eicosapentaenoic acid (20:5n-3) (EPA) were investigated. Findings indicated reduced lipid deposition, increase in metabolites associated with β-oxidation, and significant reduction in fatty acid levels in the liver, implying improvement in fatty liver condition. Concomitant administration of L-carnitine and EPA resulted in further benefits, via changes in fatty acid composition in the medaka fatty liver model.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>28584294</pmid><doi>10.1038/s41598-017-02924-5</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2045-2322
ispartof Scientific reports, 2017-06, Vol.7 (1), p.2749-10, Article 2749
issn 2045-2322
2045-2322
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_56d754f1cc8f4367970dc3b3c98f3e0e
source Open Access: PubMed Central; Publicly Available Content Database (Proquest) (PQ_SDU_P3); Free Full-Text Journals in Chemistry; Springer Nature - nature.com Journals - Fully Open Access
subjects 101/58
631/443/319/2723
631/443/319/320
82/1
Alcohol use
Animals
Biomarkers
Body Weight
Carnitine
Carnitine - pharmacology
Diet, High-Fat
Disease Models, Animal
Eicosapentaenoic acid
Fatty acid composition
Fatty acids
Fatty Acids - metabolism
Fatty liver
Fatty Liver - drug therapy
Fatty Liver - etiology
Fatty Liver - metabolism
Fatty Liver - pathology
Humanities and Social Sciences
Lipid Metabolism - drug effects
Liver
Liver - drug effects
Liver - metabolism
Liver - pathology
Liver diseases
Liver Function Tests
Metabolites
Metabolome
Metabolomics - methods
Mitochondria
Mitochondria - drug effects
Mitochondria - metabolism
multidisciplinary
Oryzias - metabolism
Oryzias latipes
Oxidation
Oxidation-Reduction - drug effects
Science
Science (multidisciplinary)
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
title Evaluation of the effects of L-carnitine on medaka (Oryzias latipes) fatty liver
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T09%3A51%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20the%20effects%20of%20L-carnitine%20on%20medaka%20(Oryzias%20latipes)%20fatty%20liver&rft.jtitle=Scientific%20reports&rft.au=Fujisawa,%20Koichi&rft.date=2017-06-05&rft.volume=7&rft.issue=1&rft.spage=2749&rft.epage=10&rft.pages=2749-10&rft.artnum=2749&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-017-02924-5&rft_dat=%3Cproquest_doaj_%3E1906465744%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c606t-dfa4e171f62b597ac7f084cfa44ee007a5364c1f7a8004cfc493eef546b7b8543%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1955544871&rft_id=info:pmid/28584294&rfr_iscdi=true